CCND1 and liver cancer: APS (both 100 and 200 mg/L) can suppress the activity of the Wnt/β-catenin pathway by downregulating the mRNA and protein expression of β-catenin, C-myc, and cyclin D1, as well as by inhibiting the antiapoptotic gene Bcl-2, thereby inducing apoptosis in HepG2 liver cancer cells [51].